<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000428262"><TermName>tumor vasculature–targeted tumor necrosis factor alpha</TermName><TermPronunciation>(TOO-mer VAS-kyoo-luh-cher-TAR-geh-ted TOO-mer neh-KROH-sis FAK-ter AL-fuh)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. It is made by linking tumor necrosis factor (TNF) to a peptide. The peptide binds to tumor blood vessels, and TNF damages them. It is a type of biological response modifier. Also called NGR-TNF.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713303" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tumor vasculature–targeted tumor necrosis factor alpha&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713302" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;factor de necrosis tumoral alfa dirigido a la vasculatura tumoral&quot;" language="es" id="_4"/><SpanishTermName>factor de necrosis tumoral alfa dirigido a la vasculatura tumoral</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Se elabora al enlazar el factor de necrosis tumoral (FNT) con un péptido. El péptido se une a los vasos sanguíneos del tumor y el FNT los daña. Es un tipo de modificador de la respuesta biológica. También se llama NGR-TNF.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-05-23</DateFirstPublished><DateLastModified>2008-11-14</DateLastModified></GlossaryTerm>
